Collaboration and License Agreements (Tables)

3 Months Ended

Mar. 31, 2022

Collaboration And License Agreements [Abstract]

Summary of Allocation of Total Transaction Price and Unsatisfied Transaction Price

The following table summarizes the allocation of the total transaction price to the identified performance obligations under the Roche Agreement, and the amount of the transaction price unsatisfied as of March 31, 2022 (in thousands):

12

	Transaction Price Allocated		Transaction Price Unsatisfied
Performance obligations:
Research and development targets	$	58,851	$	26,109
Option rights		6,721		3,502
Total	$	65,572	$	29,611

Schedule of Revenue from Collaboration Agreements

Revenue from collaboration agreements for the three months ended March 31, 2022 and 2021 in the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):

	Three Months Ended March 31,
	2022		2021
Revenue from collaboration agreements:
Roche Agreement	$	1,123	$	2,193
Biogen Agreement		4,716		1,880
Calico Agreement		1,815		3,353
Total revenue from collaboration agreements	$	7,654	$	7,426

Schedule of Financial Information Related to Collaboration and License Agreements

Financial information related to the collaboration and license agreements consisted of the following in the Company’s condensed consolidated balance sheet as of March 31, 2022 (in thousands):

	Accounts Receivable		Deferred Revenue, Current		Deferred Revenue, Net of Current		Deferred Revenue, Total
Supplemental information:
Roche Agreement	$	500	$	6,021	$	16,173	$	22,194
Biogen Agreement		—		23,078		2,847		25,925
Calico Agreement		1,273		2,167		—		2,167
Total	$	1,773	$	31,266	$	19,020	$	50,286

Financial information related to the collaboration and license agreements consisted of the following in the Company’s condensed consolidated balance sheet as of December 31, 2021 (in thousands):

	Accounts Receivable		Deferred Revenue, Current		Deferred Revenue, Net of Current		Deferred Revenue, Total
Supplemental information:
Roche Agreement	$	1,215	$	5,601	$	17,215	$	22,816
Biogen Agreement		3,000		24,032		6,611		30,643
Calico Agreement		1,501		2,167		542		2,709
Total	$	5,716	$	31,800	$	24,368	$	56,168

Schedule of Supplemental Financial Information Related to Collaboration and License Agreements

Supplemental financial information related to the collaboration and license agreements for the three months ended March 31, 2022 and 2021 are (in thousands):

	Three Months Ended March 31,
	2022		2021
Revenue recognized that was included in the contract liability at the beginning of the period	$	6,267	$	4,519
Revenue recognized from performance obligations fully or partially satisfied in previous periods		115		—